title: Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
abstract: Between 4/91 and 12/93, 262 patients received cadaveric (CRT) (n = 205) or living donor (LRT) (non-HLA identical) renal transplants. All patients were treated with the same sequential induction immunosuppression protocol, with the exception of different forms of antilymphocyte sera: either Minnesota antilymphocyte globulin (MALG), antithymocyte globulin (ATG), orthoclone antibody (OKT3), d 1 postoperatively, or OKT3 intraoperatively. With the withdrawal of MALG from the market, we wished to prospectively analyze the influence of these other antilymphocyte therapies on the incidence of delayed graft function (DGF) (the requirement for hemodialysis within the first week postoperatively) and renal function during the first 3 d postoperatively and during the subsequent .6 months post-transplantation and compare that with our MALG experience. Of the 205 CRT, 76 received MALG with a DGF rate of 18.4%, 50 received ATGAM with a DGF rate of 22.0%, 38 received OKT3 postoperatively with a DGF rate of 39.5%, and 41 received OKT3 intraoperatively with a DGF rate of 39%. Of the 57 LRT, only two patients, one receiving intraoperatively OKT3 (secondary to graft thrombosis), and one MALG patient, suffered DGF. Serum creatinine values were obtained from postoperative d 1 through postoperative d 4 for 185 patients. Each of the four groups showed similar mean decrements in serum creatinine. The number of grafts functioning at 1, 2, 3 and 6 months postoperatively and serum creatinine values were not statistically different between the groups. We conclude that induction immunosuppression with MALG and ATGAM is associated with a lower DGF rate than OKT3 given either intraoperatively or postoperatively. However, with 6 months of follow-up, we do not observe any difference in the incidence of rejection or graft function between the therapies. Consequently, we have chosen ATGAM as our preferred inductive therapy in the absence of MALG owing to its lower associated DGF rate.
authors.affiliation: Department of Medicine, University of Maryland School Medicine, Baltimore 21201, USA.
authors.forename: L
authors.initials: L
authors.lastname: Malinow
authors.forename: J
authors.initials: J
authors.lastname: Walker
authors.forename: D
authors.initials: D
authors.lastname: Klassen
authors.forename: D
authors.initials: D
authors.lastname: Oldach
authors.forename: E
authors.initials: E
authors.lastname: Schweitzer
authors.forename: S T
authors.initials: ST
authors.lastname: Bartlett
authors.forename: M R
authors.initials: MR
authors.lastname: Weir
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007430:Intraoperative Care; D007674:Kidney Diseases / Q000209:etiology; D016030:Kidney Transplantation; D008297:Male; D016853:Muromonab-CD3 / Q000008:administration & dosage*; D011182:Postoperative Care; D011183:Postoperative Complications; D011446:Prospective Studies; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D003404:Creatinine